日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.

PI3Kα抑制剂和降解剂Inavolisib可利用FGFR2增强PIK3CA突变实体瘤患者和临床前模型的疗效。

Juric Dejan, Song Kyung, Johnson Radia M, Accordino Melissa K, Bedard Philippe L, Cervantes Andrés, Gambardella Valentina, Hamilton Erika, Italiano Antoine, Kalinsky Kevin, Krop Ian E, Oliveira Mafalda, Saura Cristina, Schmid Peter, Turner Nicholas C, Varga Andreea, Gendreau Steven, Hwang Michael S, Kuang Zheng, Lau Jeffrey T, Lin Eva, Pham Trang, Maddalo Danilo, Rees Matthew G, Ronan Melissa M, Roth Jennifer A, Martin Scott, Sodir Nicole M, Sokol Ethan S, Whitfield Zachary J, Wong Alice, Yauch Robert L, Aimi Junko, Cheeti Sravanthi, Fredrickson Jill, Hilz Stephanie, Hafner Marc, Hutchinson Katherine E, Jin Yanling, Peters Ubong, Zingg Daniel, Royer-Joo Stephanie, Shankar Noopur, Schutzman Jennifer L, Jhaveri Komal L, Dey Anwesha

Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancer.

配体激活的 EGFR/MAPK 信号通路(而非 PI3K)是结直肠癌中 EGFR 疗法产生耐药性的关键机制

Qu Xueping, Hamidi Habib, Johnson Radia M, Sokol Ethan S, Lin Eva, Eng Cathy, Kim Tae Won, Bendell Johanna, Sivakumar Smruthy, Kaplan Benjamin, de Sousa E Melo Felipe, Mancini Andrew, Wongchenko Matthew, Shi Yi, Shames David, Yan Yibing, Ciardiello Fortunato, Bais Carlos

Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma

构建基于基因表达的IDH野生型胶质母细胞瘤预后特征

Johnson, Radia M; Phillips, Heidi S; Bais, Carlos; Brennan, Cameron W; Cloughesy, Timothy F; Daemen, Anneleen; Herrlinger, Ulrich; Jenkins, Robert B; Lai, Albert; Mancao, Christoph; Weller, Michael; Wick, Wolfgang; Bourgon, Richard; Garcia, Josep

Cascade: an RNA-seq visualization tool for cancer genomics

Cascade:一款用于癌症基因组学的RNA-seq可视化工具

Shifman, Aaron R; Johnson, Radia M; Wilhelm, Brian T